Your Health, We Care
Olaparib, as a polyadenosine diphosphate ribose polymerase (PARP) inhibitor, has made significant progress in the field of cancer treatment in recent years.
The United States Food and Drug Administration (FDA) has approved olaparib for the treatment of HER2-negative metastatic breast cancer harboring BRCA gene mutations, bringing new hope to BRCA mutant breast cancer patients.
